Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5702582 | 0.96 | LMNA (0.44) | LMNAALDH1A1TSHRFGFR4TP53 | |
| SCHEMBL727397 | 0.80 | — | — | |
| SCHEMBL8094858 | 0.80 | LMNA (0.37) | LMNAALDH1A1TSHRFGFR4TP53 | |
| SCHEMBL403345 | 0.78 | — | — | |
| SCHEMBL1825536 | 0.78 | — | — | |
| SCHEMBL9356506 | 0.78 | — | — | |
| SCHEMBL2751659 | 0.76 | — | — | |
| SCHEMBL28994050 | 0.76 | CA4 (0.37) | LMNAALDH1A1TSHRFGFR4 | |
| SCHEMBL30353586 | 0.72 | ALDH1A1 (0.35) | LMNAALDH1A1TSHRTP53 | |
| SCHEMBL28414098 | 0.72 | LMNA (0.30) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2110 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116950-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2026-04-30 | — | — | US | disclosed |
| US-20260116918-A1 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2026-04-30 | — | — | US | disclosed |
| US-20260028387-A1 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2026-01-29 | — | — | US | disclosed |
| US-20250235519-A1 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-07-24 | — | — | US | disclosed |
| US-20250223335-A1 | PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST HEAD AND NECK SQUAMOUS CELL CARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-07-10 | — | — | US | disclosed |
| US-12351616-B2 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-07-08 | — | — | US | disclosed |
| WO-2025136809-A2 | FOXP3 PEPTIDES AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-12318407-B2 | Peptides displayed by HLA for use in immunotherapy against different types of cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-06-03 | — | — | US | disclosed |
| US-20250154459-A1 | PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-05-15 | — | — | US | disclosed |
| US-12297245-B2 | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-05-13 | — | — | US | disclosed |
| EP-0284406-B1 | Biologically active molecules | PITMAN MOORE LTD (GB) | 1994-09-14 | — | — | EP | disclosed |
| WO-1993020213-A1 | NISINS | AGRICULTURE AND FOOD RESEARCH COUNCIL (GB) | 1993-10-14 | — | — | WO | disclosed |
| WO-1993014209-A1 | VACCINES BASED ON STREPTOKINASE | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |
| WO-1993007872-A1 | LYSOSOMAL ENZYME INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | THE UNIVERSITY OF NOTTINGHAM (GB) | 1993-04-29 | — | — | WO | disclosed |
| EP-0405763-A1 | GRF peptides | MALLINCKRODT VETERINARY LIMITED (GB) | 1991-01-02 | — | — | EP | disclosed |
| WO-1990015073-A1 | GRF PEPTIDES | COOPERS ANIMAL HEALTH LIMITED (GB) | 1990-12-13 | — | — | WO | disclosed |
| WO-1989009226-A1 | PEPTIDES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1989-10-05 | — | — | WO | disclosed |
| EP-0335662-A1 | Peptides | BTG INTERNATIONAL LIMITED (GB) | 1989-10-04 | — | — | EP | disclosed |
| WO-1988007547-A1 | BIOLOCICALLY ACTIVE MOLECULES | COOPERS ANIMAL HEALTH LIMITED (GB) | 1988-10-06 | — | — | WO | disclosed |
| EP-0284406-A1 | Biologically active molecules | PITMAN-MOORE LIMITED (GB) | 1988-09-28 | — | — | EP | disclosed |